Late-onset hypogonadism – Wikipedia
Posted: April 1, 2018 at 3:43 pm
Late-onset hypogonadism is a rare condition in older men, characterized by measurably low testosterone levels and clinical symptoms mostly of a sexual nature, including decreased desire for sex, fewer spontaneous erections, and erectile dysfunction.[1] It is the result of a gradual drop in testosterone; a steady decline in testosterone levels of about 1% per year can happen and is well documented in both men and women.[2][3]
Late-onset hypogonadism is an endocrine condition as well as a result of aging.[1]
The terms "male menopause" and "andropause" are used in the popular media and are misleading, as they imply a sudden change in hormone levels similar to what women experience in menopause.[4]
As of 2016, the International Society for the Study of the Aging Male defines late-onset hypogonadism as a series of symptoms in older adults related to testosterone deficiency that combines features of both primary and secondary hypogonadism; the European Male Aging Study (a prospective study of ~3000 men)[5] defined the condition by the presence of at least three sexual symptoms (e.g. reduced libido, reduced spontaneous erections, and erectile dysfunction) and total testosterone concentrations less than 11 nmol/l (3.2ng/ml) and free testosterone concentrations less than 220 pmol/l (64 pg/ml).[1]
Some men present with the symptoms, but with normal testosterone levels, and some men with low testosterone levels have no symptoms; the reasons for this are not known.[1][6]
Some men in their late 40s and early 50s develop depression, loss of libido, erectile dysfunction, and other physical and emotional symptoms such as irritability, loss of muscle mass and reduced ability to exercise, weight gain, lack of energy, difficulty sleeping, or poor concentration; many of these symptoms may arise from a midlife crisis or as the results of a long-term unhealthy lifestyle (smoking, excess drinking, overeating, lack of exercise) and may be best addressed by lifestyle changes, therapy, or antidepressants.[4]
If a person has symptoms of late-onset hypogonadism, testosterone is measured by taking blood in the morning on at least two days; while immunoassays are commonly used, mass spectrometry is more accurate and is becoming more widely available.[6] The meaning of the measurement is different depending on many factors that affect how testosterone is made and how it is carried in the blood. Increased concentrations of proteins that bind testosterone in blood occur if the person is older, has hyperthyroidism or liver disease, or is taking anticonvulsant drugs (which are increasingly used for depression and various neuropathies), and decreased concentrations of proteins that bind testosterone occur if the person is obese, has diabetes, has hypothyroidism, has liver disease, or is taking glucocorticoids or androgens, or progestins.[6] If levels are low, conditions that cause primary and secondary hypogonadism need to be ruled out.[6][7][8]
Due to difficulty and expense of testing, and the ambiguity of the results, screening is not recommended.[1][6] While some clinical instruments (standard surveys) had been developed as of 2016, their specificity was too low to be useful clinically.[1]
Testosterone levels can and are well-documented to decline with aging at about 1% per year in both men and women after a certain age; the causes are not well understood.[1][2][3][9][10]
The significance of a decrease in testosterone levels is debated and its treatment with replacement is controversial. The Food and Drug Administration (FDA) stated in 2015 that neither the benefits nor the safety of testosterone have been established in older men with low testosterone levels.[11] Testosterone replacement therapy should only be started if low levels have been confirmed;[7] in the US, this confirmation is not done about 25% of the time, as of 2015.[8] Testosterone levels should also be monitored during therapy.[7]
Adverse effects of testosterone supplementation may include increased cardiovascular (CV) events (including strokes and heart attacks) and deaths, especially in men over 65 and men with pre-existing heart conditions.[1] The potential for CV risks from testosterone therapy led the FDA to issue a requirement in 2015 that testosterone pharmaceutical labels include warning information about the possibility of an increased risk of heart attacks and stroke.[1][11] However, the data are mixed, so the European Medicines Agency, the American Association of Clinical Endocrinologists, and the American College of Endocrinology have stated that no consistent evidence shows that testosterone therapy either increases or decreases cardiovascular risk.[1]
Other significant adverse effects of testosterone supplementation include acceleration of pre-existing prostate cancer growth; increased hematocrit, which can require venipuncture to treat; and, exacerbation of sleep apnea.[1]
Adverse effects may also include minor side effects such as acne and oily skin, as well as significant hair loss and/or thinning of the hair, which may be prevented with 5-alpha reductase inhibitors ordinarily used for the treatment of benign prostatic hyperplasia, such as finasteride or dutasteride.[12]
Exogenous testosterone may also cause suppression of spermatogenesis, leading to, in some cases, infertility.[1]
As of 2015, the evidence is inconclusive as to whether testosterone replacement therapy can help with erectile dysfunction in men with late-onset hypogonadism.[8] It appears that testosterone replacement therapy may benefit men with symptoms of frailty who have late-onset hypogonadism.[8]
The epidemiology is not clear; 20% of men in their 60s and 30% of men in their 70s have low testosterone;[2][8] around 5% of men between 70 and 79 have both low testosterone and the symptoms, so are diagnosed with late-onset hypogonadism.[2] The National Health Service describes it as rare.[4]
The impact of low levels of testosterone has been previously reported. In 1944, Heller and Myers identified symptoms of what they labeled the "male climacteric" including loss of libido and potency, nervousness, depression, impaired memory, the inability to concentrate, fatigue, insomnia, hot flushes, and sweating. Heller and Myers found that their subjects had lower than normal levels of testosterone, and that symptoms decreased dramatically when patients were given replacement doses of testosterone.[13][14]
Popular interest in the concept of "andropause" was fueled by the 1998 book Male Menopause, written by Jed Diamond, a lay person.[15] According to Diamond's view, andropause is a change of life in middle-aged men, which has hormonal, physical, psychological, interpersonal, social, sexual, and spiritual aspects. Diamond claims that this change occurs in all men, may occur as early as age 45 to 50 and more dramatically after the age of 70 in some men, and that women's and men's experiences are somewhat similar phenomena.[16][17] The language of "andropause" and its supposed parallels with menopause have been rejected by the medical community.[4][18]
Thomas Perls and David J. Handelsman, in a 2015 editorial in the Journal of the American Geriatrics Society, say that between the ill-defined nature of the diagnosis and the pressure and advertising from drug companies selling testosterone and human growth hormone, as well as dietary supplement companies selling all kinds of "boosters" for aging men, the condition is overdiagnosed and overtreated.[19] Perls and Handelsman note that in the US, "sales of testosterone increased from $324 million in 2002 to $2 billion in 2012, and the number of testosterone doses prescribed climbed from 100 million in 2007 to half a billion in 2012, not including the additional contributions from compounding pharmacies, Internet, and direct-to-patient clinic sales."[19]
As of 2016, research was necessary to find better ways to measure testosterone and to be better able to understand the measurements in any given person, and to understand why some people with low testosterone do not present with symptoms and some with seemingly adequate levels do present with symptoms.[1] Research was also necessary to better understand the cardiovascular risks of testosterone replacement therapy in older men.[1]
A relationship between late-onset hypogonadism and risk of Alzheimer's disease and some small clinical studies have been conducted to prevent Alzheimer's disease in men with late-onset hypogonadism; as of 2009, results were inconclusive.[20]
Read more:
Late-onset hypogonadism - Wikipedia
- Testosterone Treatment and Fractures in Men with Hypogonadism | NEJM - nejm.org - January 20th, 2024
- Understanding Hypogonadism, Testosterone Replacement Therapy, and Prostate Cancer Risk - Medriva - January 11th, 2024
- Male hypogonadism - Patient Information - January 3rd, 2024
- Testosterone replacement therapy may not increase risk of prostate cancer among men with hypogonadism - Medical Dialogues - January 3rd, 2024
- Male Hypogonadism Market Expected to Reach $5.1 Billion by 2030 | Current Trends and Industry Analysis - EIN News - December 16th, 2023
- Hypogonadism: What Is It, Causes, Signs and Symptoms, and More - Osmosis - November 2nd, 2023
- Hypogonadism - StatPearls - NCBI Bookshelf - February 10th, 2023
- Male hypogonadism: Symptoms and treatment - PMC - PubMed Central (PMC) - February 10th, 2023
- The 'male menopause' - NHS - November 26th, 2022
- Diagnosis of Hypogonadism: Clinical Assessments and Laboratory Tests - November 1st, 2022
- Approach to the Patient With Hypogonadotropic Hypogonadism - November 1st, 2022
- Clomiphene citrate for men with hypogonadism: a systematic ... - PubMed - September 21st, 2022
- Hypogonadism in females | DermNet - September 21st, 2022
- Clomiphene citrate effects on testosterone/estrogen ratio in male ... - September 21st, 2022
- Male Hypogonadism Market Size to Grow by USD 684.95 Mn, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio - Longview News-Journal - September 21st, 2022
- Male sexual health and reproductive medicine: All that glitters is not gold - Urology Times - September 21st, 2022
- The Reproductive Outcome of Women with HH in IVF - Physician's Weekly - August 20th, 2022
- Men's Health Market is Slated to Witness Tremendous Growth in Coming Years | Latest Report by IBI - Digital Journal - August 20th, 2022
- Why Can Some Medicines Increase The Risk Of Osteoporosis? - Nation World News - August 20th, 2022
- What is Erectile dysfunction (aka ED)? : Buy Kamagra to treat the ED - My MMA News.com - August 20th, 2022
- Sure Signs Your Endocrine System Isn't as Strong as it Should Be Eat This Not That - Eat This, Not That - August 11th, 2022
- What has the NFL said about Packers QB Rodgers consuming ayahuasca? - AS USA - August 11th, 2022
- Male hypogonadism: Symptoms, causes, and treatment - Medical News Today - July 8th, 2022
- Hypogonadism in Men | Endocrine Society - July 8th, 2022
- Olfactory Radioanatomical Findings in Patients With Cardiac Arrhythmias, COVID-19, and Healthy Controls - Cureus - July 8th, 2022
- Global Hormone Replacement Therapy Market Is Projected To Thriving At A CAGR of 1.51% During 2022-2028 | 120 Report Pages - Digital Journal - July 8th, 2022
- Testosterone May Aid Memory in Men With Uncontrolled Diabetes - Everyday Health - June 28th, 2022
- Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review - Cureus - June 28th, 2022
- EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody in Switzerland - Business... - April 28th, 2022
- Tucker Carlson hawks testicle tanning to boost testosterone. Experts say it may do the opposite - Salon - April 28th, 2022
- A practical guide to male hypogonadism in the primary care ... - January 1st, 2022
- Waist Circumference Is More Closely Associated with Hypogonadism than Is Hyperglycemia, Independent of BMI in Middle-Aged Men - DocWire News - January 1st, 2022
- Andrological aspects of new coronavirus infection Covid-19 - DocWire News - January 1st, 2022
- Reviewing the Top 5 Best Male Enhancement Pills in 2022 to Buy - The Daily World - January 1st, 2022
- Low Sex Drive (Hypogonadism): Symptoms, Treatment - December 22nd, 2021
- Androgen Deprivation Therapy and the Risk for Inguinal Hernia: An Observational Nested Case Control Study - DocWire News - December 22nd, 2021
- 5 Best Testosterone Boosters to Increase Testosterone Levels in 2022 - Us Weekly - December 22nd, 2021
- Male hypogonadism | You and Your Hormones from the Society ... - November 21st, 2021
- Low testosterone predicts hypoxemic respiratory insufficiency and mortality in patients with COVID-19 disease: another piece in the COVID puzzle -... - November 21st, 2021
- CLARUS THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) -... - November 21st, 2021
- Bio-Identical Hormone Replacement Therapy Market to Rise Due to the Increasing Applications and Wider Reach, Players Pfizer Bayer. Energy Siren -... - November 21st, 2021
- Hormone Replacement Therapy Market Rise in Sustainability Around The World 2021 2030 - Taiwan News - October 5th, 2021
- 6 Things To Look for In a Good Testosterone Booster Supplement - The Portugal News - October 5th, 2021
- Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer - DocWire News - October 5th, 2021
- [PDF] Hormone Replacement Therapy Market to Reflect Steady Growth and Future Scope UNLV The Rebel Yell - UNLV The Rebel Yell - August 30th, 2021
- Top 6 Benefits of Testosterone Therapy Times Square Chronicles - Times Square Chronicles - August 3rd, 2021
- Hormone Replacement Therapy Market by 2027 Worldwide Growth Opportunities Recent Trends Forecast by Types and Application to 2027 The Manomet Current... - August 3rd, 2021
- 9 Ways to Increase Testosterone Naturally in 2021 - Men's Journal - August 3rd, 2021
- Testosterone Therapy for Hypogonadism Guideline Resources ... - May 26th, 2021
- Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And... - May 26th, 2021
- Trending Report of Male Hypogonadism Market Drivers, Strategies, Applications and Competitive Landscape 2026 Brockville Observer - Brockville... - May 26th, 2021
- Male menopause: Here's everything you need to know about andropause - Pulse Ghana - May 26th, 2021
- Blue Water Acquisition : Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory... - May 26th, 2021
- Hormone Replacement Therapy Market Size to Surpass US$ 36.54 Billion by 2027 with the CAGR of 8.20% The Manomet Current - The Manomet Current - May 26th, 2021
- The many effects of reproductive hormones on the brain - ESHRE - May 26th, 2021
- Hormone Replacement Therapy (HRT) Market to Eyewitness Stunning Growth by 2027 Covid-19 Analysis The Shotcaller - The Shotcaller - May 26th, 2021
- The Male Hypogonadism Market To Witness Steadfast Growth In The Next 10 Years The Courier - The Courier - May 14th, 2021
- The Male Hypogonadism Market To Ride On Innovations KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - May 14th, 2021
- Hormone Replacement Therapy Market Global Industry Scope and Growth Analysis Report 2021: Opportunity Assessment, Business Boosting Strategies, and... - May 14th, 2021
- Global Hormone Replacement Therapy (HRT) Industry Market Report 2020, Forecast Till 2027 By Type, End-use, Geography and Player The Courier - The... - May 14th, 2021
- Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr... - UroToday - February 11th, 2021
- Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News - Jumbo News - February 11th, 2021
- The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy's Hockey Law - Murphy's Hockey Law - February 3rd, 2021
- Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday - February 3rd, 2021
- Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX... - January 29th, 2021
- Male Hormone Replacement Therapy And The Side Effects - Nerd's Magazine - January 29th, 2021
- New York Medical and Life Sciences: Year in Review 2020 - JD Supra - January 29th, 2021
- Male menopause: symptoms, diagnosis and treatment - Netdoctor - January 29th, 2021
- Freeman: 'Pressure to Succeed' Led to Testosterone Order - Medscape - January 27th, 2021
- Hormone Replacement Therapy Market Growth Analysis,Size,Insight,Share And Outlook By 2027 Pfizer, AbbVie, Novo Nordisk NeighborWebSJ - NeighborWebSJ - January 27th, 2021
- Male Hypogonadism Therapy Market to Witness Massive Growth During 2021-2027 | Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - January 25th, 2021
- Male Hypogonadism Therapy Market and Ecosystem by Production, Prospects, Consumption, Cost Structure, Competitive Landscape - Jumbo News - January 25th, 2021
- What is Harvey Prices disability Prader-Willi Syndrome? - The Sun - January 25th, 2021
- The Male Hypogonadism Market To Witness An Escalating CAGR Of 3.7% - NeighborWebSJ - January 19th, 2021
- Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo... - January 19th, 2021
- Global COVID-19 Diagnostics Market Size Worth USD 11.40 Billion at 7.9% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for... - January 19th, 2021
- Marius Pharmaceuticals Submits New Drug Application to US FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With... - January 12th, 2021
- Testosterone Replacement Therapy Market (2020 2027) Explosive Factors of Revenue by Key Manufacturer, Share, Future Trends, COVID-19 Market Scenario,... - January 9th, 2021
- The Anabolic Steroids Market to sharpen in the next decade - The Monitor - January 9th, 2021
- Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report - DocWire News - December 24th, 2020